• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.

作者信息

Waldschmidt Johannes M, Sotudeh Noori, Arora Sankalp, Vijaykumar Tushara, Anand Praveen, Stuart Hannah, Frede Julia, Campbell Tim, Kaiser Shari M, Zheng Xirong, Munshi Nikhil C, Anderson Kenneth C, Einsele Hermann, Yee Andrew J, Knoechel Birgit, Lohr Jens G, Raje Noopur S

机构信息

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Harvard Medical School, Boston, MA.

出版信息

Blood Adv. 2025 Mar 11;9(5):1132-1136. doi: 10.1182/bloodadvances.2024015285.

DOI:10.1182/bloodadvances.2024015285
PMID:39813623
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11914164/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b7/11914164/9e5394fd7448/BLOODA_ADV-2024-015285-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b7/11914164/9e5394fd7448/BLOODA_ADV-2024-015285-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96b7/11914164/9e5394fd7448/BLOODA_ADV-2024-015285-gr1.jpg

相似文献

1
Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.纳武单抗恢复CAR-T难治性多发性骨髓瘤中的T细胞适应性。
Blood Adv. 2025 Mar 11;9(5):1132-1136. doi: 10.1182/bloodadvances.2024015285.
2
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial.抗GPRC5D嵌合抗原受体T细胞疗法作为抗BCMA嵌合抗原受体T细胞疗法后进展性多发性骨髓瘤患者的挽救治疗：一项单中心、单臂、2期试验
Lancet Haematol. 2025 May;12(5):e365-e375. doi: 10.1016/S2352-3026(25)00048-1. Epub 2025 Apr 12.
3
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.双特异性抗体作为复发/难治性多发性骨髓瘤与BCMA嵌合抗原受体T细胞疗法之间的桥梁。
Blood Cancer Discov. 2025 Jan 8;6(1):38-54. doi: 10.1158/2643-3230.BCD-24-0118.
4
IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.分泌白细胞介素-18 的多抗原靶向嵌合抗原受体 T 细胞在免疫功能正常的小鼠模型中消除低抗原骨髓瘤。
Blood. 2024 Jul 11;144(2):171-186. doi: 10.1182/blood.2023022293.
5
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.当前抗骨髓瘤嵌合抗原受体T细胞：新靶点与新方法
Balkan Med J. 2025 Jul 1;42(4):301-310. doi: 10.4274/balkanmedj.galenos.2025.2025-4-25.
6
Focusing on Selinexor for Holding and Bridging Prior to CAR-T in Relapsed/Refractory Multiple Myeloma.在复发/难治性多发性骨髓瘤中，在进行嵌合抗原受体T细胞（CAR-T）治疗之前，关注塞利尼索用于维持和过渡治疗。
J Clin Med. 2025 Jun 9;14(12):4071. doi: 10.3390/jcm14124071.
7
Myeloma cell-intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.骨髓瘤细胞内在的膜联蛋白A1升高和T细胞功能障碍导致CAR-T治疗后BCMA阴性复发。
Mol Ther. 2025 Jul 2;33(7):3375-3391. doi: 10.1016/j.ymthe.2025.03.001. Epub 2025 Mar 8.
8
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model.在BCMA嵌合抗原受体T细胞（BCMA-CART）细胞疗法背景下，阻断TIGIT在多发性骨髓瘤小鼠模型中并不会增强疗效。
Oncoimmunology. 2025 Dec;14(1):2529632. doi: 10.1080/2162402X.2025.2529632. Epub 2025 Jul 12.
9
Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.同种异体抗 BCMA CAR T 细胞在临床前研究中优于多发性骨髓瘤衍生的 CAR T 细胞，并且可能与 γ 分泌酶抑制剂联合使用。
Cancer Res Commun. 2022 Mar 23;2(3):158-171. doi: 10.1158/2767-9764.CRC-21-0157. eCollection 2022 Mar.
10
An Assessment of the Effectiveness and Safety of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma Patients with Relapsed or Refractory Disease: A Systematic Review and Meta-Analysis.嵌合抗原受体 T 细胞疗法治疗复发/难治性多发性骨髓瘤患者的有效性和安全性评估：系统评价和荟萃分析。
Int J Mol Sci. 2024 May 3;25(9):4996. doi: 10.3390/ijms25094996.

引用本文的文献

1
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma.多发性骨髓瘤中针对BCMA的双特异性抗体和CAR T细胞疗法的耐药机制
Cells. 2025 Jul 15;14(14):1077. doi: 10.3390/cells14141077.

本文引用的文献

1
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.CD8 效应 T 细胞增强了 BCMA 暴露和未暴露的多发性骨髓瘤患者对 teclistamab 的反应。
Blood Adv. 2024 Apr 9;8(7):1600-1611. doi: 10.1182/bloodadvances.2023011225.
2
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
3
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
预先存在的T细胞格局决定了多发性骨髓瘤患者对双特异性T细胞衔接器的反应。
Cancer Cell. 2023 Apr 10;41(4):711-725.e6. doi: 10.1016/j.ccell.2023.02.008. Epub 2023 Mar 9.
4
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.伊达赛利珠单抗或标准方案治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2023 Mar 16;388(11):1002-1014. doi: 10.1056/NEJMoa2213614. Epub 2023 Feb 10.
5
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.骨髓肿瘤和免疫细胞的变化与骨髓瘤患者接受 BCMA CAR T 治疗后的缓解持续时间相关。
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
6
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
7
A cross-talk between CAR T cell subsets and the tumor microenvironment is essential for sustained cytotoxic activity.CAR T 细胞亚群与肿瘤微环境之间的串扰对于持续的细胞毒性活性至关重要。
Sci Immunol. 2021 Mar 26;6(57). doi: 10.1126/sciimmunol.abd4344.
8
Mechanisms of response and resistance to CAR T cell therapies.嵌合抗原受体 T 细胞疗法的反应和耐药机制。
Curr Opin Immunol. 2021 Apr;69:56-64. doi: 10.1016/j.coi.2021.02.010. Epub 2021 Mar 19.
9
B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy.在一名骨髓瘤患者接受基于挽救性程序性细胞死亡蛋白1抑制剂的联合治疗后，B细胞成熟抗原嵌合抗原受体T细胞的重新扩增
Br J Haematol. 2021 May;193(4):851-855. doi: 10.1111/bjh.17397. Epub 2021 Mar 13.
10
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.伊达比星脂质体注射用多柔比星治疗复发/难治性多发性骨髓瘤
N Engl J Med. 2021 Feb 25;384(8):705-716. doi: 10.1056/NEJMoa2024850.